Quality by design strategy of human mesenchymal stem/stromal cell drug products for the treatment of knee osteoarthritis

doi:10.4252/wjsc.v17.i5.106547

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (182)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-1)

Sum=101

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=46

Publishing Process of This Article

Item

Count

Browse

Download

Sum=24

May 26, 2025 (publication date) through May 29, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. May 26, 2025; 17(5): 106547
Published online May 26, 2025. doi: 10.4252/wjsc.v17.i5.106547

Open in New Tab Full Size Figure Download Figure

Figure 1 Summary of quality by design process for the production of mesenchymal stem/stromal cells. CQA: Critical quality attributes; QTPP: Quality Target Product Profile; CMA: Critical material attributes; CPP: Critical process parameters; PDT: Population doubling time.

Open in New Tab Full Size Figure Download Figure

Figure 2 The critical quality attributes-related clinical mechanism of mesenchymal stem/stromal cell-based therapy for knee osteoarthritis. CQA: Critical quality attributes; VEGF: Vascular endothelial growth factor; IL-6: Interleukin-6; IDO: Indoleamine 2,3-dioxygenase; TSG6: Tumor necrosis factor-stimulated gene 6; MSC: Mesenchymal stem/stromal cell; BMP-2: Bone morphogenetic protein 2; TNF: Tumor necrosis factor; TGF-β: Transforming growth factor beta; PGE2: Prostaglandin E2; Tregs: Regulatory T cells.

Citation: Yu H, Zhang F, He YC, Zhang LS. Quality by design strategy of human mesenchymal stem/stromal cell drug products for the treatment of knee osteoarthritis. World J Stem Cells 2025; 17(5): 106547
URL: https://www.wjgnet.com/1948-0210/full/v17/i5/106547.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i5.106547